Compare Adaptive Biotechnologies Corp (ADPT) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs ProShares Ultra Semiconductors — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while ProShares Ultra Semiconductors trades at $90.61. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals.
| ADPT | USD | |
|---|---|---|
Market Cap | $4.05B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $25.45 | $113.53 |
52-Week Low | $12.30 | $40.97 |
Enterprise Value | $4.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
USD stock trades at $93.67, up 3.46% in the past 24 hours, with technical indicators signaling a bullish trend. The stock shows strong momentum above key support levels, though the RSI_6 at 99.69 suggests overbought conditions. A dividend of $0.14 is scheduled for June 30, 2026. Recent news highlights corporate developments in financial services and technology sectors.
The outlook remains positive given bullish technical signals and corporate actions, but high RSI indicates potential near-term pullback risks. Investors should weigh the dividend yield against valuation concerns amid limited fundamental data availability. Market sentiment is mixed, with institutional interest balanced by overbought technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
